Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gain Therapeutics Inc (GANX)

Gain Therapeutics Inc (GANX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,379
  • Shares Outstanding, K 26,525
  • Annual Sales, $ 60 K
  • Annual Income, $ -22,270 K
  • EBIT $ -21 M
  • EBITDA $ -21 M
  • 60-Month Beta 0.21
  • Price/Sales 757.17
  • Price/Cash Flow N/A
  • Price/Book 4.41

Options Overview Details

View History
  • Implied Volatility 261.88% ( +113.81%)
  • Historical Volatility 96.19%
  • IV Percentile 77%
  • IV Rank 31.93%
  • IV High 762.43% on 12/11/24
  • IV Low 27.07% on 06/10/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 181
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 3,240
  • Open Int (30-Day) 1,715

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.19
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -0.23
  • Prior Year -0.29
  • Growth Rate Est. (year over year) +34.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5000 +4.00%
on 12/20/24
1.8950 -17.68%
on 11/25/24
-0.1000 (-6.02%)
since 11/20/24
3-Month
1.4502 +7.57%
on 09/23/24
3.1900 -51.10%
on 10/17/24
+0.1300 (+9.09%)
since 09/20/24
52-Week
0.8900 +75.28%
on 08/13/24
5.3300 -70.73%
on 02/07/24
-0.8800 (-36.07%)
since 12/20/23

Most Recent Stories

More News
Gain Therapeutics, Inc. to Present at Biotech Showcase 2025 on GT-02287 for Parkinson's Disease

Gain Therapeutics will present on GT-02287, a Parkinson's disease treatment, at Biotech Showcase 2025.Quiver AI SummaryGain Therapeutics, Inc. has announced that Gene Mack, its Chief Financial Officer...

GANX : 1.5600 (-0.64%)
Gain Therapeutics To Present At Biotech Showcase 2025

GANX : 1.5600 (-0.64%)
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

GANX : 1.5600 (-0.64%)
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2

GANX : 1.5600 (-0.64%)
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GANX : 1.5600 (-0.64%)
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference

GANX : 1.5600 (-0.64%)
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

GANX : 1.5600 (-0.64%)
Gain Therapeutics to Participate at Upcoming Investor Conferences

GANX : 1.5600 (-0.64%)
Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update

Presented Additional Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and...

GANX : 1.5600 (-0.64%)
Gain Therapeutics to Participate at the Jefferies Healthcare Conference

BETHESDA, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming...

GANX : 1.5600 (-0.64%)

Business Summary

Gain Therapeutics Inc. is redefining drug discovery with its See-Tx(TM) target identification platform. It involved in identifying and optimizing allosteric binding sites which have never before been targeted. The company is unlocking new treatment options for difficult-to-treat disorders characterized...

See More

Key Turning Points

3rd Resistance Point 1.8733
2nd Resistance Point 1.7867
1st Resistance Point 1.6733
Last Price 1.5600
1st Support Level 1.4733
2nd Support Level 1.3867
3rd Support Level 1.2733

See More

52-Week High 5.3300
Fibonacci 61.8% 3.6339
Fibonacci 50% 3.1100
Fibonacci 38.2% 2.5861
Last Price 1.5600
52-Week Low 0.8900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar